A phase I/II study is ongoing for RRMM and newly diagnosed MM to determine the RP2D of CC-92480 in combination with standard treatments (bortezomib, carfilzomib, anti-CD38 mAbs, etc.)(NCT03989414). The gene discussed is CD38; the disease is Miyoshi myopathy.